| |
| |
|
| Insider
Information: |
Sharp Shalini |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
215,117 |
|
|
Indirect Shares
|
104,270 |
|
|
| Direct
Value |
$4,317,035 |
|
|
|
Indirect Value
|
$46,244 |
|
|
| Total
Shares |
319,387 |
|
|
| Total
Value |
$4,363,279 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 537.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Agenus Inc |
AGEN |
Director |
2013-01-30 |
81,311 |
2015-09-28 |
104,270 |
Premium* |
|
|
Ultragenyx Pharmaceutical Inc |
RARE |
EVP, Finance |
2020-10-14 |
97,812 |
|
0 |
Premium* |
|
|
Nuvation Bio Ord Shs Class A |
NUVB |
Director |
2021-02-10 |
35,000 |
2021-02-10 |
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2024-01-23 |
0 |
2021-03-26 |
0 |
Premium* |
|
|
Neurocrine Biosciences Inc |
NBIX |
Director |
2024-05-17 |
994 |
2024-05-17 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
130 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 6 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,444 |
9,414 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
Director |
– • – |
2023-12-29 |
4 |
A |
$58.75 |
$399,970 |
D/D |
6,808 |
16,222 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
• • – |
2024-01-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(16,222) |
0 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,100 |
2,100 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-05-17 |
4 |
AS |
$141.90 |
$156,943 |
D/D |
(1,106) |
994 |
0 |
% |
|
130 Records found
|
|
Page 6 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
